Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "ABB"

439 News Found

AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib
News | August 23, 2025

AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib

The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study


AbbVie to invest $195 million to expand API manufacturing in North Chicago
News | August 16, 2025

AbbVie to invest $195 million to expand API manufacturing in North Chicago

The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines


AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients
Drug Approval | August 06, 2025

AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients

The submission is supported by positive results from the Phase 3 AMPLIFY trial


AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata
Clinical Trials | August 06, 2025

AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata

The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage


AbbVie to acquire Capstan Therapeutics for $2.1 billion
Biotech | July 01, 2025

AbbVie to acquire Capstan Therapeutics for $2.1 billion

Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo


AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study
Clinical Trials | June 21, 2025

AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study

TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month


FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C
Drug Approval | June 13, 2025

FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C

Now approved for both acute and chronic HCV in adults and children aged 3 and above


Abbott India posts Q4 FY25 net profit at Rs. 367.04 Cr
News | May 18, 2025

Abbott India posts Q4 FY25 net profit at Rs. 367.04 Cr

The company has posted net profit of Rs. 1,414.44 crores for the Financial Year ended March 31, 2025


Abbott India elevates Maithilee Pathare Mistry as CFO
People | April 21, 2025

Abbott India elevates Maithilee Pathare Mistry as CFO

Mistry is a seasoned finance professional having an extensive work experience spanning more than 25 years


Abbott India elevates Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy
People | April 17, 2025

Abbott India elevates Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy

Anushree has been with Abbott since 2021 and currently serving as Head of Strategy and Portfolio